Skip to content

Study · Observational study · n = 5,366 · 2014

2 results

Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine.

Pawaskar M, Tuttle KR, Li Q, Best JH, Anderson PW

The Annals of pharmacotherapy4 Feb 2014Cited by 23 (Europe PMC)

PMID24497624 (opens in a new tab)DOI10.1177/1060028013520597 (opens in a new tab)PepBankPUB-24497624
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In type 2 diabetes, exenatide treatment was linked to no significant difference in follow-up eGFR versus glargine.

    In plain wordsExenatide treatment was linked to similar kidney filtration compared with glargine after one year.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeFollow-up eGFR
    Study

    n = 5,366

    Comparator
    Insulin glargine
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    eGFR
    78 mL/min/1.73 m(2)
    exenatide BID
    eGFR
    80 mL/min/1.73 m(2)
    insulin glargine

    Source sentences

    Summary
    At 1-year follow-up, there was no significant difference in mean eGFR between the groups (78 mL/min/1.73 m(2) for exenatide BID vs 80 mL/min/1.73 m(2) for insulin glargine; P = .39).
    2 context sentences
    Summary · context
    Retrospective analyses were performed using an electronic medical record database.
    Summary · context
    The 2 groups were 1:1 propensity score matched on baseline variables yielding 2683 pairs.
  2. 02HumanObservational studyEfficacy outcome

    In type 2 diabetes, exenatide treatment was linked to no significant difference in UACR change versus glargine.

    In plain wordsExenatide treatment was linked to a similar change in urine albumin ratio compared with glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeUACR change
    Study

    n = 5,366

    Comparator
    Insulin glargine
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    UACR change
    104 mg/g
    exenatide BID
    UACR change
    −47 mg/g
    insulin glargine

    Source sentences

    Summary
    At follow-up, exenatide BID patients had a mean increase in UACR of 104 mg/g, insulin glargine patients had a decrease of 47 mg/g, but the difference was not significant (P = .19).
    2 context sentences
    Summary · context
    Retrospective analyses were performed using an electronic medical record database.
    Summary · context
    The 2 groups were 1:1 propensity score matched on baseline variables yielding 2683 pairs.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.